Total Credits: 1 including 1 AOA Category 1-A Credit(s)
As the seventh leading cause of death in the United States, diabetes is a national epidemic affecting 30 million people. Even with the deluge of new information, clinical study results and widening pipelines of new medications, patients are still suffering complications and dying at an alarming rate. Physicians must be able to combine new pharmaceutical classes, technology and treatment guidelines to improve diabetes management that translates to decreased morbidity and mortality.
At the conclusion of this session, the participant should be able to:
- Discuss the prevention and delay of type 2 diabetes.
- Describe the recent guidelines in diabetes care
Disclosure: Dr. Jeffrey Freeman, faculty for this educational event, is on the speaker’s bureau for Novo Nordisk. All relevant financial relationships listed have been mitigated.
Accreditation Statement: The Pennsylvania Osteopathic Medical Association (POMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. POMA designates this activity for a maximum of 1.0 Category 1-A AOA CME credits and will report CME and specialty credits to the AOA commensurate with the extent of the physician’s participation in this activity.
Grievance Statement: If you are not satisfied with the program, you may file a written grievance by emailing cme@poma.org. Your complaint will be forwarded to the Education Committee for review. The committee will determine if the participant should be reimbursed with no credits or deny the complaint and take the issue into consideration for future programs.
| POMA23-FreemanJeffrey (3.2 MB) | Available after Purchase | ||
Jeffrey S. Freeman, DO, FACOI, FACP, “Type 2 Diabetes: So Many Meds, So Many Directions,” is professor of internal medicine and chairman of the division of endocrinology and metabolism at the Philadelphia College of Osteopathic Medicine, and a physician with HAN Endocrinology Associates, Chester Crozer Medical Center in Springfield, Pennsylvania. Board certified in internal medicine, endocrinology and clinical lipidology, Dr. Freeman is a graduate of the University of Hartford in West Hartford, Connecticut, and a 1978 graduate of Des Moines (Iowa) University — Osteopathic Medical Center College of Osteopathic Medicine and Surgery. He completed an internship at Pontiac (Mich.) Osteopathic Hospital, an internal medicine residency at John F. Kennedy Memorial Hospital in Stratford, New Jersey, and an endocrinology and metabolism fellowship at the University of Medicine and Dentistry of New Jersey in Newark. A fellow of the American College of Osteopathic Internists and the American College of Physicians, Dr. Freeman is a member of POMA, the Philadelphia County Osteopathic Medical Society, the American Osteopathic Association, the New Jersey Association of Osteopathic Physicians and Surgeons, past president of the American Diabetes Association Pennsylvania affiliate, the American Heart Association, the Thyroid Society of Philadelphia and board member of the Philadelphia Endocrinology Society.
Dr. Freeman, faculty for this educational event, is on the speaker’s bureau for Novo Nordisk, Bayer, Mannkind, and Sanofi. All relevant financial relationships listed have been mitigated.
|
Current Screening for High School and College Athletes, Including Sudden Death in Sports
Original Program Date: 05/03/2023 |
|
Update in the Management of Congestive Heart Failure with Reduced Ejection Fraction in 2023
Original Program Date: 05/03/2023 |
|
Current Medical, Endovascular and Surgical Management of Carotid Artery Disease
Original Program Date: 05/03/2023 |
|
An Interdisciplinary Approach to Metabolic Disease Management with Cultural Considerations
Original Program Date: 05/04/2023 |